Amaxa and Qiagen Announce Marketing Agreement
By Biotechdaily staff writers
Posted on 15 Aug 2003
An agreement to actively co-market their complementary products involved in the transfection of siRNA (silencing RNA) oligonucleotides into cells has been announced by Amaxa GmbH (Cologne, Germany) and Qiagen N.V. (Venlo, The Netherlands). Posted on 15 Aug 2003
Amaxa has developed technology called Nucleofector as a tool for the transfection of siRNA oligonucleotides and siRNA vectors into primary cells, hard-to-transfect cells, and commonly used cell lines. Qiagen has developed high performance purity (HPP) grade siRNA oligonucleotides based on patented chemistry for effective and reproducible gene silencing. Qiagen is a supplier of oligonucleotide synthesis services and provides a large library of predeveloped siRNA molecules directed against common target genes, including cancer-related genes and the SARS coronavirus siRNA set.
"The combination of Qiagen's siRNA know-how with our ability to transfect suspension cell lines and primary cells with siRNA oligonucleotides enables us to offer our customers a complete package for the successful knock-down of specific genes,” said Rainer Christine, CEO of Amaxa.
Related Links:
Amaxa
Qiagen